Japan to press ahead with device reimbursement reform
This article was originally published in Clinica
Japan's influential government advisory body on medical reimbursement, the Chuikyo, has agreed to set up a subcommittee to look at medical device reimbursement reform. US industry, in particular, has been pushing the Japanese government for several years to move ahead on changing the device pricing system. Detailed discussions are scheduled to begin in September, according to Pharma Japan.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.